Literature DB >> 3535740

Tumoricidal effects and patient survival after hyperthermic liver perfusion.

J L Skibba, E J Quebbeman.   

Abstract

Hyperthermic liver perfusion for four hours at 42.0 degrees C to 42.5 degrees C was used as the sole modality of therapy for cancer confined to the liver in eight patients. Two patients had melanoma, one had cholangiolar carcinoma of the liver, and five had liver metastases from colorectal carcinoma. Two postoperative deaths occurred, both in patients with colorectal carcinoma metastases. Response was indicated by computed tomographic and/or liver biopsy or autopsy findings of tumor necrosis. There were five responders to hyperthermic liver perfusion among the six survivors. Hyperthermic liver perfusion was an effective tumoricidal agent for hepatic metastases from colorectal cancer; ie, tumor necrosis occurred in all five patients, as well as in the two who died, as shown by autopsy findings. Conversion to a disease-free state with hyperthermic perfusion may be possible with other treatment modalities used in combination or sequence.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535740     DOI: 10.1001/archsurg.121.11.1266

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Carlo Ori; Federico Innocente; Romano Scalerta; Mauro Ceccherini; Pier Paolo Da Pian; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

Review 2.  Isolated hepatic perfusion for patients with liver metastases.

Authors:  Srinevas K Reddy; Susan B Kesmodel; H Richard Alexander
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

3.  Simple method of hyperthermo-chemo-hypoxic isolated liver perfusion for hepatic metastases.

Authors:  M Horikawa; Y Nakajima; K Kido; S Ko; K Ohashi; H Nakano
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.